This article needs to beupdated. Please help update this article to reflect recent events or newly available information.(October 2024) |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H20F3N5O2 |
| Molar mass | 419.408 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
DSP-2230 is aselectivesmall-moleculeNav1.7 andNav1.8voltage-gated sodium channelblocker which is under development byDainippon Sumitomo Pharma for the treatment ofneuropathic pain.[1][2] As of June 2014, it is inphase I/phase IIclinical trials.[1][2]